Pharmaceutical Care for Patients Undergoing S-1 Plus Cisplatin Therapy for Unresectable Recurrent Gastric Cancer

In conclusion, we should pay attention to the safety and continuity of S-1 plus cisplatin therapy in cases where the Alb level is <3.5 g/dL, CrCl level is <78 mL/min, and PS level is >1. Pharmacists should consider reducing the treatment dosage and providing nutritional support in such cases.

Source: Journal of Pharmacy Practice - August 1, 2013 Category: Drugs & Pharmacology Authors: Kimura, M., Usami, E., Yoshimura, T., Yasuda, T., Kaneoka, Y., Teramachi, H., Sugiyama, T., Tsuchiya, T. Tags: Research Articles Source Type: research